NCT04071457 | S1803 | OPEN – Green Bay Oncology

Clinical Trial: NCT04071457 | S1803 | OPEN

NCT Number: NCT04071457

Protocol ID: S1803

Sponsor: OPEN

Disease Site: Multiple Myeloma

Disease Category: Multiple Myeloma

Detail: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

For more details, click here.

Interested in participating in this trial?

Clinical Trial

First Name

Last Name

Phone

Preferred Contact Method:

Preferred Location:

Patient Type:

Current Patient New Patient

Interested in:

Cancer Clinical Trial Blood Disorder Clinical Trial

Disease Site:

Disease Category

What do all the numbers mean on clinical trials?

National Clinical Trial Identifier

The National Clinical Trial (NTC) is assigned by the National Library of Medicine when a new study appears in the clinical trials database.

ex: NCT0526225 | GY026 | NRG

PROTOCOL IDENTIFICATION NUMBER

Any unique identifier assigned to the protocol by the sponsor.

ex: NCT0526225 | GY026 | NRG

STUDY SPONSOR

A sponsor is an individual, institution, company or organization that takes the responsibility to initiate, manage and/or finance the clinical trial.

ex: NCT0526225 | GY026 | NRG